Suchergebnisse - "Hu, Huabin"

PubPharm (11)

1

First-line pembrolizumab plus chemotherapy for extensive-stage small-cell lung cancer : a United States-based cost-effectiveness analysis

enthalten in: Cost effectiveness and resource allocation : C/E | 2021

von Zhu, Y. | Hu, H. | Ding, D. | +4

2

First-line pembrolizumab plus chemotherapy for extensive-stage small-cell lung cancer: a United States-based cost-effectiveness analysis

enthalten in: Cost effectiveness and resource allocation | 2021

von Zhu, Y. | Hu, H. | Ding, D. | +4

3

Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA

enthalten in: Advances in therapy | 2021

von Li, S. | Hu, H. | Ding, D. | +2

4

Cost-Effectiveness of Pembrolizumab plus Axitinib Versus Sunitinib as First-Line Therapy in Advanced Renal Cell Carcinoma in the U.S

enthalten in: The oncologist | 2021

von Ding, D. | Hu, H. | Shi, Y. | +6

5

Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA

enthalten in: Advances in therapy | 2021

von Li, S. | Hu, H. | Ding, D. | +2

6

Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA

enthalten in: Advances in therapy | 2021

von Li, S. | Hu, H. | Ding, D. | +2

7

Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA

enthalten in: Advances in therapy | 2021

von Li, S. | Hu, H. | Ding, D. | +2

8

Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer

enthalten in: Advances in therapy | 2020

von Ding, D. | Hu, H. | Liao, M. | +6

9

Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer

enthalten in: Advances in therapy | 2020

von Ding, D. | Hu, H. | Liao, M. | +6

10

Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer

enthalten in: Advances in therapy | 2020

von Ding, D. | Hu, H. | Liao, M. | +6